Skip to main content
Premium Trial:

Request an Annual Quote

Athersys Gets Rights to Minnesota Stem Cells

NEW YORK, Dec. 11-Athersys has obtained exclusive rights to University of Minnesota stem cell technology in order to study stem cell differentiation and develop new therapeutics, the company said this morning.


The company acquired rights to research done with Multipotent Adult Progenitor Cells, a type of stem cell isolated from adult bone marrow. Stem cell researchers hope these may be developed as a treatment for conditions like muscular dystrophy or Parkinson's disease.


In this agreement, researchers from Athersys and from the University of Minnesota hope to jointly identify the proteins that direct cell differentiation using the company's gene expression technology. These proteins may also suggest new leads for drug development.


The partners are making the cells available to academic researchers through material transfer agreements.


Financial specifics of the license and partnership were not revealed.


Athersys is based in Cleveland, Ohio.


For further information, see the statement.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.